Health Care • Biotechnology: Pharmaceutical Preparations
$2.64 ▲ +0.07
(+2.72%)
MKT CAP: $2.1M • VOL: 6.7K
52W L $3 52W H $1,492
ROARABLE / RQD
D- • 36/100
PIOTROSKI
3 / 9
ELAB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $590.1K | $0 | $1.7M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $185.3K | — | — |
| Gross Margin % | 31.4% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $0 | $0 | $0 |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$7.7M | -$6.2M | -$4.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.9M | -$5.5M | -$4.6M |
| Capital Expenditures (CapEx) | $442.3K | $9.2K | — |
| Free Cash Flow (FCF) | -$6.4M | -$5.5M | -$4.6M |
| FCF Margin % | -80.0% | — | -80.0% |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | — | $4.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $7.8M | $6.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ELAB.